

ORIGINAL RESEARCH

# Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study

Teddy Tai Loy Lee <sup>ID</sup>; Jeremy Man Ho Hui <sup>ID</sup>; Yan Hui Athena Lee; Danish Iltaf Satti <sup>ID</sup>; Yuki Ka Ling Shum <sup>ID</sup>, MPharm; Pias Tang Hoi Kiu, MBBS; Abraham Ka Chung Wai <sup>ID</sup>, MBChB; Tong Liu <sup>ID</sup>, MD, PhD; Wing Tak Wong <sup>ID</sup>, PhD; Jeffrey Shi Kai Chan <sup>ID</sup>, MBChB; Bernard Man Yung Cheung <sup>ID</sup>, MB BChir, PhD; Ian Chi Kei Wong <sup>ID</sup>, PhD; Shuk Han Cheng <sup>ID</sup>, PhD; Gary Tse <sup>ID</sup>, MD, PhD

**BACKGROUND:** Commonly prescribed diabetic medications such as metformin and sulfonylurea may be associated with different arrhythmogenic risks. This study compared the risk of ventricular arrhythmia or sudden cardiac death between metformin and sulfonylurea users in patients with type 2 diabetes.

**METHODS AND RESULTS:** Patients aged  $\geq 40$  years who were diagnosed with type 2 diabetes or prescribed antidiabetic agents in Hong Kong between January 1, 2009, and December 31, 2009, were included and followed up until December 31, 2019. Patients prescribed with both metformin and sulfonylurea or had prior myocardial infarction were excluded. The study outcome was a composite of ventricular arrhythmia or sudden cardiac death. Metformin users and sulfonylurea users were matched at a 1:1 ratio by propensity score matching. The matched cohort consisted of 16596 metformin users (47.70% men; age,  $68 \pm 11$  years; mean follow-up,  $4.92 \pm 2.55$  years) and 16596 sulfonylurea users (49.80% men; age,  $70 \pm 11$  years; mean follow-up,  $4.93 \pm 2.55$  years). Sulfonylurea was associated with higher risk of ventricular arrhythmia or sudden cardiac death than metformin hazard ratio (HR, 1.90 [95% CI, 1.73–2.08]). Such difference was consistently observed in subgroup analyses stratifying for insulin usage or known coronary heart disease.

**CONCLUSIONS:** Sulfonylurea use is associated with higher risk of ventricular arrhythmia or sudden cardiac death than metformin in patients with type 2 diabetes.

**Key Words:** metformin ■ sudden cardiac death ■ sulfonylurea ■ type 2 diabetes ■ ventricular arrhythmia

Type 2 diabetes is a highly prevalent condition worldwide; 1 in 11 adults globally have type 2 diabetes. Every year, it causes over 1 million deaths, making it the ninth leading cause of mortality.<sup>1</sup> Cardiovascular complications are significantly associated with death among patients with type 2 diabetes,<sup>2</sup>

with ventricular arrhythmia and sudden cardiac death (VA/SCD) being the most common macrovascular complications.<sup>3</sup> Siscovick and colleagues estimated the incidence rate of sudden cardiac arrest to be 3.15 per 1000 patients with diabetes without prior clinically recognized heart disease; and the incident rate

Correspondence to: Shuk Han Cheng, PhD, Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China. Email: [bhcheng@cityu.edu.hk](mailto:bhcheng@cityu.edu.hk) and Gary Tse, MD, PhD, FRCP, FFPH, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China. Kent and Medway Medical School, Canterbury, United Kingdom. Email: [garytse86@gmail.com](mailto:garytse86@gmail.com)

Preprint posted on Research Square February 2, 2022. doi: <https://doi.org/10.21203/rs.3.rs-1309807/v1>

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026289>

For Sources of Funding and Disclosures, see page 8.

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: [www.ahajournals.org/journal/jaha](http://www.ahajournals.org/journal/jaha)

## CLINICAL PERSPECTIVE

### What Is New?

- Sulfonylurea use is associated with a higher risk of ventricular arrhythmias and sudden cardiac death compared with metformin use.
- Our results show higher incidence of ventricular arrhythmias and sudden cardiac death in tolbutamide users compared with other sulfonylureas.

### What Are the Clinical Implications?

- The findings of this study highlight the importance of moving away from using sulfonylureas in type 2 diabetes control.

## Nonstandard Abbreviations and Acronyms

<b>SCD</b>	sudden cardiac death
<b>VA</b>	ventricular arrhythmia

was 13.80 per 1000 patients with diabetes with clinically recognized heart disease, 3.84 and 2.31 times higher when compared with patients without diabetes, respectively.<sup>4</sup> The elevated risk can be attributed to a poor glycemic control and other risk factors such as dyslipidemia and nephropathy.<sup>4</sup>

Metformin and sulfonylurea were frequently prescribed because of their effective glycemic control and low cost even though their cardiovascular risks continue to be debated.<sup>5</sup> The effect of antidiabetic medications on atrial fibrillation has been well documented,<sup>6,7</sup> yet not many studies investigated the effect of such medications on the risk of VA/SCD, let alone the comparison between metformin and sulfonylurea use. There is a need for the above investigation as sudden cardiac death, the most devastating manifestation of VA, is the leading cause of death among patients with type 2 diabetes with cardiovascular complications.<sup>8</sup>

Therefore, this study aimed to compare the risk of developing VA/SCD between metformin and sulfonylurea users.

## METHODS

### Data Source

This study has been approved by the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee. This was a population-based retrospective cohort study. Data

were extracted from the Clinical Data Analysis and Reporting System, a territory-wide electronic database storing patient health care records managed by the Hong Kong Hospital Authority, which manages 42 hospitals, 47 specialist outpatient clinics, and 73 general outpatient clinics, serving a population of 7 million. This database has previously been used for cohort studies by local teams in Hong Kong.<sup>9–11</sup> The need for informed consent was waived because of the observational nature and the use of deidentified data in this study. The data that support the findings of this study are available from the corresponding author upon reasonable request.

### Study Cohort

Patients who fulfilled all of the following inclusion criteria were included: (1) aged  $\geq 40$  years; and (2) had documented diagnosis of type 2 diabetes under the *International Classification of Diseases, Ninth Revision (ICD-9)* coding system, or were prescribed antidiabetic agents between January 1, 2009, and December 31, 2009. Patients who were prescribed both metformin and sulfonylurea or had past medical history of myocardial infarction, as identified using *ICD-9* codes, were excluded from the study.

### Outcomes

The primary outcome of the study is a composite of ventricular arrhythmia and sudden cardiac death (VA/SCD), as identified using *ICD-9* codes. A diagnosis of VA/SCD was made on the basis of clinical judgment by the treating physician and was then coded according to the *ICD-9* system into the Clinical Data Analysis and Reporting System. VA/SCD episodes in which a myocardial infarction occurred within 1 week before or after the VA/SCD episode were considered acute myocardial infarction related and thus excluded. Patients were followed up until December 31, 2019.

### Propensity Score Matching

To facilitate comparability of the cohorts, propensity score matching was performed with the baseline demographics of sex, age, and duration since type 2 diabetes diagnosis; prior comorbidities including peripheral vascular disease, ischemic stroke, atrial fibrillation, heart failure, prior VA/SCD, intracranial hemorrhage, coronary heart disease, hypertension, and chronic obstructive pulmonary disease; baseline medication use including angiotensin-converting enzyme inhibitors, beta blockers, calcium channel blockers, diuretics, and use of diabetic medications including insulin, thiazolidinediones, dipeptidyl-peptidase 4 inhibitors, and glucagon-like peptide agonists; and laboratory tests of hemoglobin A<sub>1c</sub>. The *ICD-9* codes used

for classification of the corresponding medical conditions are available in Table S1.

Imputation was not performed; patients with missing data were excluded during the generation of the matched cohort. Patients with use of either metformin or sulfonylurea were matched on a 1:1 ratio on the propensity score, which was derived from logistic regression using the nearest-neighbor matching algorithm. To assess the balance of covariates, the standardized mean difference, which is the difference in means or proportions over the pooled SD, was used for categorical covariates, while the variance ratio, which is the ratio of variance between the treatment and control groups, was used for both categorical and continuous covariates. A caliper width of 0.2 was chosen as it is considered as the optimal caliper width for estimating mean differences.<sup>12</sup> Covariates were considered balanced in both groups when the standardized mean difference was <0.1, and when the variance ratio was between 0.5 and 2.0.<sup>13</sup>


### Statistical Analysis

Continuous variables were presented as the mean (SD), and categorical variables were presented as frequency (%). Hazard ratios (HRs), along with 95% CIs and *P* values were reported accordingly with the univariate Cox proportional hazards regression model. The proportional hazards assumption of the model was assessed by performing the Schoenfeld proportionality test; the results indicated that the assumption was met. Kaplan-Meier curves were plotted against the time-to-event for VA/SCD stratified by either metformin or sulfonylurea use. The log-rank test was performed to investigate the statistical significance between the metformin and sulfonylurea groups. Incidence rates for VA/SCD were presented as incidence per 1000 person-years along with 95% CIs. Subgroup analyses were conducted to investigate the risk of VA/SCD by users versus nonusers of insulin and patients with versus without prior coronary heart disease, and by different types of sulfonylurea. Sensitivity analysis was performed by excluding patients with prior cardiomyopathy or valvular disease and excluding patients with prior heart failure. Computed E-values for HRs were computed to quantify the effects of any unmeasured confounding on our study. The E-value is defined as the minimum strength of association that an unmeasured confounder would be required to have with both the outcome and treatment to fully explain away a specific association between the treatment and outcome, conditional on the measured covariates.<sup>14</sup> In this study, a large E-value implies that an unmeasured confounder must be very strong to explain away the effect of sulfonylurea over metformin use in the risk of developing VA/SCD.

All probability tests were 2-tailed and considered significant at  $P < 0.05$ . No imputation was performed for missing data. Statistical analyses were conducted using RStudio 1.4.1717 (RStudio, Boston, Massachusetts).

## RESULTS

The steps for the selection of patients for this study cohort are shown in Figure 1. In total, 261 308 patients fulfilled the inclusion criteria. After excluding patients with missing data, the study cohort consisted of 43 167 patients (47.3% men; mean baseline age, 68±12 years), where 22 807 (52.83%) patients received metformin and 20 360 (47.17%) patients received sulfonylurea. After 1:1 propensity score matching, the final study cohort consisted of 16 596 metformin users and 16 596 matched sulfonylurea users. The baseline and clinical characteristics of the study population before and after propensity score matching are shown in Table 1. A Love plot summarizing covariate balances before and after propensity score matching is provided in Figure S1. Standardized mean difference values were <0.1 and variance ratio values were within 0.5 to 2.0,



**Figure 1. Study flowchart.**

**Table 1. Baseline Characteristics Before and After 1:1 Propensity Score Matching**

Characteristics	Before matching		After matching			
	Metformin (n=22807)	Sulfonylurea (n=20360)	Metformin (n=16596)	Sulfonylurea (n=16596)	SMD	VR
Demographics						
Male, n (%)	9797 (43.0)	10619 (52.2)	7911 (47.7)	8272 (49.8)	0.02	...
Baseline age, y	65.17±11.61	71.31±11.39	68.14±10.89	69.60±11.35	0.13	1.09
Follow-up duration since type 2 diabetes diagnosis, y	4.98±2.56	4.92±2.55	4.92±2.55	4.93±2.55	<0.01	1.00
Comorbidities						
Peripheral vascular disease, n (%)	61 (0.3)	29 (0.1)	29 (0.2)	27 (0.2)	<0.01	...
Ischemic stroke, n (%)	971 (4.3)	1419 (7.0)	859 (5.2)	986 (5.9)	<0.01	...
Atrial fibrillation, n (%)	775 (3.4)	1547 (7.6)	734 (4.4)	966 (5.8)	0.01	...
Heart failure, n (%)	814 (3.6)	2258 (11.1)	795 (4.8)	1259 (7.6)	0.03	...
Prior VA/SCD, n (%)	4 (0.0)	11 (0.1)	4 (0.0)	7 (0.0)	<0.01	...
Intracranial hemorrhage, n (%)	322 (1.4)	517 (2.5)	306 (1.8)	362 (2.2)	<0.01	...
Coronary heart disease, n (%)	2480 (10.9)	3618 (17.8)	2188 (13.2)	2529 (15.2)	0.02	...
Hypertension, n (%)	6947 (30.5)	8964 (44.0)	5904 (35.6)	6537 (39.4)	0.04	...
Chronic obstructive pulmonary disease, n (%)	60 (0.3)	135 (0.7)	58 (0.3)	90 (0.5)	<0.01	...
Medications						
ACE inhibitors, n (%)	12 795 (56.1)	11 141 (54.7)	8848 (53.3)	9025 (54.4)	0.01	...
Beta blockers, n (%)	8988 (39.4)	8372 (41.1)	6838 (41.2)	6837 (41.2)	<0.01	...
Calcium channel blockers, n (%)	9598 (42.1)	9997 (49.1)	7529 (45.4)	7810 (47.1)	0.02	...
Diuretics, n (%)	4382 (19.2)	6096 (29.9)	3761 (22.7)	4292 (25.9)	0.03	...
Insulin, n (%)	6616 (29.0)	2661 (13.1)	2429 (14.6)	2501 (15.1)	<0.01	...
Thiazolidinediones, n (%)	260 (1.1)	225 (1.3)	169 (1.0)	176 (1.1)	<0.01	...
DPP4 inhibitors, n (%)	45 (0.2)	11 (0.1)	12 (0.1)	10 (0.1)	<0.01	...
GLP-1 agonists, n (%)	9 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	<0.01	...
Glicazide, n (%)	...	13 093 (64.3)	...	10 390 (62.6)	...	...
Glipizide, n (%)	...	669 (3.3)	...	516 (3.1)	...	...
Tolbutamide, n (%)	...	698 (3.4)	...	489 (2.9)	...	...
Glibenclamide, n (%)	...	1559 (7.7)	...	1306 (7.9)	...	...
Glimepiride, n (%)	...	275 (1.4)	...	227 (1.4)	...	...
Laboratory tests						
Hemoglobin A <sub>1c</sub> , %	7.45±1.44	7.44±1.45	7.44±1.44	7.45±1.45	<0.01	1.02

Continuous variables were expressed as mean±standard deviation. SMD <0.1/VR>0.5 and <2.0 indicated good balance in matching. ACE indicates angiotensin-converting enzyme; DPP4, dipeptidyl-peptidase 4; GLP-1, glucagon-like peptide 1; SMD, standardized mean difference; VA/SCD, ventricular arrhythmia or sudden cardiac death; and VR, variance ratio.

indicating a good balance in baseline characteristics between the two cohorts; the only exception was age, which had a standardized mean difference of 0.13, but the variance ratio value was 1.09, which was very close to 1.0, indicative of good balance.<sup>15</sup>

The main and subgroup analysis of VA/SCD risk are presented in Table 2. The mean follow-up duration was 4.92±2.55 years for the metformin cohort, and 4.93±2.55 years for the sulfonylurea cohort. During the study period, 711 metformin users and 1328 sulfonylurea users experienced episodes of VA/SCD. Cox proportional hazards model analyses over the entire follow-up showed that sulfonylurea use was associated with an overall higher risk of VA/SCD than metformin

use (HR, 1.90 [95% CI, 1.73–2.08]), as visualized by the Kaplan-Meier curves in Figure 2. The corresponding E-value was 3.21.

Subgroup analyses were performed by concurrent use of insulin and the presence of coronary heart disease; sensitivity analysis was performed by excluding patients with either valvular heart disease or cardiomyopathy and by excluding patients with heart failure (Table 2). Baseline characteristics of the subgroups are summarized in Tables S2 through S4. Sulfonylurea was consistently associated with a higher risk of VA/SCD in patients without a history of valvular heart disease or cardiomyopathy (HR, 1.97 [95% CI, 1.79–2.17]), without a history of heart failure (HR, 1.94 [95% CI, 1.76–2.14]),

**Table 2. Main, Subgroup, and Sensitivity Analysis of VA/SCD Risk in Sulfonylurea Over Metformin Users**

Sulfonylurea vs metformin	Metformin users			Sulfonylurea users			E-value (HR)
	HR (95% CI)	Cohort size	Number of events	Follow-up person-years/incidence per 1000 person-years (95% CI)	Cohort size	Number of events	
Overall	1.90 (1.73–2.08)	16596	711	81682/8.70 (8.08–9.37)	16596	1328	81777/16.24 (15.38–17.14)
Without history of valvular heart disease/cardiomyopathy	1.97 (1.79–2.17)	15426	619	75837/8.16 (7.53–8.83)	14992	1163	74071/15.70 (14.81–16.63)
Without history of heart failure	1.94 (1.76–2.14)	15801	620	77605/7.99 (7.37–8.64)	15337	1148	77688/14.78 (13.93–15.66)
Insulin use							
Insulin users only	1.82 (1.52–2.18)	2429	181	12021/15.06 (12.94–17.42)	2501	333	12329/27.01 (24.19–30.07)
Without insulin use	1.92 (1.73–2.13)	14167	530	69660/7.61 (6.97–8.28)	14095	995	69448/14.33 (13.45–15.25)
Coronary heart disease							
Without coronary heart disease	1.95 (1.76–2.16)	14408	571	70602/8.09 (7.44–8.80)	14067	1069	69078/15.47 (14.56–16.43)
With coronary heart disease only	1.64 (1.34–2.02)	2188	140	11080/12.64 (10.63–14.91)	2529	259	12699/20.40 (17.99–23.04)

A large E-value implies that any unmeasured confounder must be strong to explain away the effect of sulfonylurea over metformin use in the risk of developing VA/SCD. HR indicates hazard ratio; and VA/SCD, ventricular arrhythmia or sudden cardiac death.

and in both insulin users (HR, 1.82 [95% CI, 1.52–2.18]) and nonusers (HR, 1.92 [95% CI, 1.73–2.13]). Similarly, sulfonylurea use was associated with higher risks of VA/SCD across those with (HR, 1.64 [95% CI, 1.34–2.02]) and without (HR, 1.95 [95% CI, 1.76–2.16]) coronary heart disease.

The risk of VA/SCD between individual types of sulfonylurea is shown in Table 3. Glicazide (HR, 1.74 [95% CI, 1.57–1.93]), glipizide (HR, 2.15 [95% CI, 1.54–3.01]) and glimepiride (HR, 2.79 [95% CI, 1.82–4.29]) were significantly associated with a higher risk of VA/SCD, with tolbutamide being associated with the highest risk (HR, 4.70 [95% CI, 3.58–6.17]). The corresponding E-values were 2.87, 3.72, 5.02, and 8.87, respectively. Baseline characteristics of individual sulfonylurea users are shown in Table S5.

## DISCUSSION

The main finding of this study is that sulfonylurea users have a higher risk of ventricular arrhythmia and sudden cardiac death than metformin users. These results were consistent irrespective of severity of diabetes or history of coronary heart disease.


### Mechanism Underlying the Observations

It is hypothesized that sulfonylurea may inhibit the delayed rectifier potassium channel, leading to prolonged QT interval.<sup>16</sup> A trial conducted in 30 patients with type 2 diabetes found that patients randomized to glyburide were associated with an increase in corrected QT interval compared with patients randomized to metformin.<sup>17</sup> Sulfonylurea carries a high risk of hypoglycemia compared with other antidiabetic medications,<sup>18</sup> in turn prolonging action potentials in myocardial tissue by blocking potassium channels at the cellular level.<sup>19</sup> Multiple studies found that severe hypoglycemia, a major concern of sulfonylurea, increased the risk of VA/SCD.<sup>20,21</sup> However, sulfonylurea may also have antiarrhythmic effects by inhibiting reentrant arrhythmias by a mechanism known as ischemic preconditioning, and thus reducing the risk of developing cardiac arrest,<sup>16</sup> but it has been suggested that the effects of ischemic preconditioning are abolished in type 2 diabetes.<sup>22</sup> Metformin has pleotropic effects with many cardiovascular benefits as shown in basic science studies<sup>23,24</sup>; it was found to be associated with a decreased corrected QT interval in animal models,<sup>25</sup> but no decrease in ventricular arrhythmic outcomes was reflected in clinical trials.<sup>26</sup>

### Comparison With Previous Observational Studies

Two recent observational studies have investigated the association between metformin and sulfonylurea use





**Figure 2.** Kaplan-Meier survival curves of VA/SCD stratified by metformin vs sulfonylurea from main and subgroup analysis. Blue=metformin, red=sulfonylurea. HR indicates hazard ratio; and VA/SCD, ventricular arrhythmia or sudden cardiac death.

and risk of VA/SCD.<sup>27,28</sup> Ostropolets and colleagues<sup>27</sup> found that patients with diabetes on metformin monotherapy had a reduced risk of VA compared with sulfonylurea monotherapy. However, patients with a history of atrial fibrillation, ventricular tachycardia, and ventricular fibrillation were excluded from their study, so their results may not be generalizable to patients with prior arrhythmic conditions. Moreover, younger patients with type 2 diabetes were not captured, as only patients aged >50 years were included in their study, which may lead to biased results. A recent systematic review has shown that type 2 diabetes is increasingly

diagnosed in patients aged <50 years in many countries worldwide.<sup>29</sup> Our study included patients with type 2 diabetes aged ≥40 years, which is more generalizable to a larger population.

Conversely, Eroglu and colleagues<sup>28</sup> found that sulfonylurea antidiabetics were associated with a lower risk of developing out-of-hospital cardiac arrest. However, their study did not match cases and controls by duration of diabetes, which is a risk factor for ventricular arrhythmias.<sup>4</sup> The duration of diabetes was accounted for during propensity score matching in our study. Moreover, age was not evenly distributed in their

**Table 3.** Subgroup Analysis of VA/SCD Risk by Individual Sulfonylurea

Sulfonylurea versus metformin	HR (95% CI)	Cohort size	Number of events	Follow-up person-years/incidence per 1000 person-years	E-value (HR)
Glicazide	1.74 (1.57–1.93)	10 116	744	49983/14.89 (13.83–15.99)	2.87
Glipizide	2.15 (1.54–3.01)	399	36	1998/18.02 (12.62–24.94)	3.72
Tolbutamide	4.70 (3.58–6.17)	302	56	1503/37.26 (28.14–48.38)	8.87
Glibenclamide	1.16 (0.89–1.51)	1216	60	6157/9.75 (7.44–12.54)	1.00*
Glimepiride	2.79 (1.82–4.29)	180	22	829/26.54 (16.63–40.18)	5.02

A large E-value implies that any unmeasured confounder must be strong to explain away the effect of sulfonylurea over metformin use in the risk of developing VA/SCD. HR indicates hazard ratio; and VA/SCD, ventricular arrhythmia or sudden cardiac death.

\*The CI of the hazard ratio crossed 1; thus, its E-value is 1.

study groups, as patients on sulfonylurea drugs alone were older (mean age, 75.2; SD, 9.7) than those on metformin alone (mean age, 69.6; SD, 10.1). Finally, their sample size was small for both patients on sulfonylurea alone (n=215) and patients on metformin alone (n=385), while our study included 16 596 metformin users and 16 596 sulfonylurea users after matching.

### Implications of Subgroup and Sensitivity Analyses

Sensitivity analysis was performed by excluding patients with a history of cardiomyopathy or valvular heart disease, as cardiomyopathies are a common cause of SCD<sup>30,31</sup>; a systematic review identified cardiomyopathies as one of the top causes of SCD in Chinese patients.<sup>32</sup> Similarly, studies have found associations of aortic valve disease and mitral valve prolapse with VA/SCD.<sup>33–36</sup> It was found that the risk for sulfonylurea compared with metformin to develop VA/SCD was similar in both sensitivity and overall analysis.

Common complications of type 2 diabetes include coronary artery disease and myopathy,<sup>37</sup> which are risk factors for developing VA/SCD.<sup>38</sup> The risk for these complications increases with the duration and severity of type 2 diabetes, which is consistent with the underlying low-grade inflammation and glycation.<sup>39,40</sup> As such, it was possible that the risk of VA/SCD increases with the duration and severity of diabetes, and the influence from medication-related effects may become less important accordingly. To better elucidate drug-related effects and minimize confounding by the above factors, we performed a subgroup analysis using insulin usage as a surrogate of diabetic duration and severity. We found that sulfonylurea was consistently associated with greater risk of developing VA/SCD than metformin regardless of diabetes severity, suggesting that the differences between these two drugs are clinically important in patients with diabetes regardless of their condition's severity and duration.

Myocardial ischemia in coronary heart disease alters metabolic and electrical processes in the heart, altering the propagation and conduction of resting and acting membrane potentials, leading to cardiac arrhythmias.<sup>41</sup> We performed subgroup analyses to explore if coronary heart disease would be a dominant risk factor for VA/SCD such that the differences in arrhythmogenicity between sulfonylurea and metformin would be considered relatively insignificant. The results of the subgroup analyses found the risk of developing VA/SCD was consistently higher in sulfonylurea users compared with metformin users even in patients with coronary heart disease. This further suggested that the differences in arrhythmogenicity between the 2 drugs were significant and clinically important regardless of patients' inherent risks for VA/SCD.

Subgroup analyses were performed to investigate the risk of VA/SCD among individual types of sulfonylurea. Glicazide, glipizide, tolbutamide, and glimepiride users were at a higher risk of VA/SCD when compared with metformin. Tolbutamide users were at the highest risk of VA/SCD, but this may be attributed to drug-induced arrhythmias because of a higher usage of proarrhythmic calcium channel blockers and beta blockers in the subgroup.<sup>42</sup>

### Clinical Implications

Although the use of sulfonylurea has decreased in recent years, it remains a commonly prescribed antidiabetic agent, second to metformin.<sup>43,44</sup> Diabetic nephropathy is a common complication among patients with type 2 diabetes with a prevalence of 31.6% in Hong Kong.<sup>45</sup> When metformin is contraindicated, such as in patients with severe kidney impairment, sulfonylurea is a viable alternative.<sup>46,47</sup> The Kidney Disease: Improving Global Outcomes 2020 guidelines recommends patients with an estimated glomerular filtration rate of  $\leq 30$  mL/min per 1.73 m<sup>2</sup> to discontinue metformin therapy.<sup>46,48</sup> However, in practice, the risk of developing VA/SCD by antidiabetic choice is often neglected. Aside from increased mortality risk, VA/SCD necessitates further therapy such as the use of implantable cardioverter-defibrillators and antiarrhythmic agents and thereby imposes more health care burden.<sup>49</sup> Patient adherence to metformin may be difficult because of the common side effect of gastrointestinal disturbance,<sup>50</sup> but this can be avoided with alternative formulations such as extended-release metformin.<sup>51</sup> Given the findings of our study, there exists a compelling case to move away from prescribing sulfonylurea for glycemic control.

### Study Limitations

This study has limitations. As this study was retrospective in nature, the effect of unmeasured confounders on the risk of developing VA/SCD cannot be ruled out. For instance, smoking status and alcohol consumption are not recorded by the Clinical Data Analysis and Reporting System. Nonetheless, we have included multiple significant risk factors in the propensity score matching. A proportion of patients were excluded for use of both metformin and sulfonylurea in our study; however, patients on both agents were not included in this comparative study, as they may be suffering from more severe type 2 diabetes compared with patients on either one of the antidiabetics. As patients without hemoglobin A<sub>1c</sub> values were excluded from the study, the results may not be generalizable to patients with mild type 2 diabetes, who are not necessarily indicated for routine hemoglobin A<sub>1c</sub> testing. Furthermore, the E-value suggested that the observed

association of the higher VA/SCD risk in sulfonylurea over metformin users would only be insignificant if an unmeasured risk factor exists with an HR of 2.67 to 3.35. A previous study by Chao and colleagues<sup>52</sup> investigated the risk of VA/SCD in subgroups by comorbidity status, some of which were unmeasured confounders not included in our propensity score model, including end-stage renal disease (HR, 2.20 [95% CI, 1.91–2.54]), malignancy (HR, 1.98 [95% CI, 1.71–2.31]), autoimmune diseases (HR, 1.93 [95% CI, 1.67–2.22]), and liver cirrhosis (HR, 1.98 [95% CI, 1.61–2.44]). None of these confounders exceeded our lowest E-value (range, 2.67–3.21). Therefore, the risk of bias caused by unmeasured confounders in our study remains low.

While we have investigated the risk of VA/SCD among different sulfonylureas, the limited use of some sulfonylureas does not allow effective comparisons to be made. Further research comparing risk of VA/SCD between different drugs of the sulfonylurea class is warranted, such that clinicians can avoid choosing select sulfonylureas with high arrhythmogenic risk.

To conclude, this study found that among patients diagnosed with type 2 diabetes, use of sulfonylurea was associated with higher risk of developing VA/SCD compared with use of metformin. The increased risk was consistent in patients with severe diabetes and in those with a history of coronary heart disease. Hence, the use of sulfonylurea should be reconsidered in patients at risk of VA/SCD. Further studies are warranted to study the risk of VA/SCD in different drugs of the sulfonylurea class.

## ARTICLE INFORMATION

Received March 29, 2022; accepted June 23, 2022.

### Affiliations

Department of Emergency Medicine, School of Clinical Medicine (T.T.L.L., A.K.C.W.), Division of Clinical Pharmacology, School of Clinical Medicine (B.M.Y.C.), and Department of Pharmacology and Pharmacy (I.C.K.W.), The University of Hong Kong, Hong Kong, China; Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China (T.T.L.L., J.M.H.H., Y.H.A.L., D.I.S., Y.K.L.S., P.T.H.K., J.S.K.C., G.T.); Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China (T.L., G.T.); School of Life Sciences, State Key Laboratory of Agrobiotechnology (CUHK), The Chinese University of Hong Kong, Hong Kong, China (W.T.W.); UCL School of Pharmacy, Medicines Optimisation Research and Education (CMORE), London, United Kingdom (I.C.W.); Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China (S.H.C.); and Kent and Medway Medical School, Canterbury, United Kingdom (G.T.).

### Sources of Funding

None.

### Disclosures

None.

### Supplemental Material

Tables S1–S5  
Figure S1

## REFERENCES

- Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020;10:107–111. doi: 10.2991/jeqh.k.191028.001
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018;14:88–98. doi: 10.1038/nrendo.2017.151
- Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. *Curr Vasc Pharmacol*. 2020;18:110–116. doi: 10.2174/1570161117666190405165151
- Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. *Rev Endocr Metab Disord*. 2010;11:53–59. doi: 10.1007/s11154-010-9133-5
- Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, Schoenherr H, Vill D, Oberdanner J, Eiselndle E, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. *BMJ Open Diabetes Res Care*. 2020;8:e001279. doi: 10.1136/bmjdr-2020-001279
- Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. *PLoS One*. 2018;13:e0197245. doi: 10.1371/journal.pone.0197245
- Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. *Diabetes Obes Metab*. 2019;21:210–217. doi: 10.1111/dom.13512
- Walker AM, Cubbon RM. Sudden cardiac death in patients with diabetes mellitus and chronic heart failure. *Diab Vasc Dis Res*. 2015;12:228–233. doi: 10.1177/1479164115573225
- Chan JSK, Zhou J, Lee S, Li A, Tan M, Leung KSK, Jeevaratnam K, Liu T, Roeber L, Liu Y, et al. Fragmented QRS is independently predictive of long-term adverse clinical outcomes in asian patients hospitalized for heart failure: a retrospective cohort study. *Front Cardiovasc Med*. 2021;8. doi: 10.3389/fcvm.2021.738417
- Mui JV, Zhou J, Lee S, Leung KSK, Lee TTL, Chou OHI, Tsang SL, Wai AKC, Liu T, Wong WT, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis. *Front Cardiovasc Med*. 2021;8:747620. doi: 10.3389/fcvm.2021.747620
- Lee S, Zhou J, Guo CL, Wong WT, Liu T, Wong ICK, Jeevaratnam K, Zhang Q, Tse G. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrinol Diabetes Metab*. 2021;4:e00240. doi: 10.1002/edm2.240
- Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat*. 2011;10:150–161. doi: 10.1002/pst.433
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res*. 2011;46:399–424. doi: 10.1080/00273171.2011.568786
- VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med*. 2017;167:268–274. doi: 10.7326/M16-2607
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med*. 2009;28:3083–3107. doi: 10.1002/sim.3697
- Leonard CE, Hennessy S, Han X, Siscovick DS, Flory JH, Deo R. Pro- and antiarrhythmic actions of sulfonylureas: mechanistic and clinical evidence. *Trends Endocrinol Metab*. 2017;28:561–586. doi: 10.1016/j.tem.2017.04.003
- Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K<sup>+</sup> channel effect. *Am J Cardiol*. 2002;90:1103–1106. doi: 10.1016/s0002-9149(02)02776-5
- Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med*. 2007;147:386–399. doi: 10.7326/0003-4819-147-6-200709180-00178
- Nordin C. The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. *Acta Diabetol*. 2014;51:5–14. doi: 10.1007/s00592-013-0528-0



20. Hsieh YC, Liao YC, Li CH, Lin JC, Weng CJ, Lin CC, Lo CP, Huang KC, Huang JL, Lin CH, et al. Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 diabetes-A nationwide cohort study. *Diabetes Metab Res Rev*. 2020;36:e3226. doi: 10.1002/dmrr.3226
21. Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, Hanefeld M. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemia and silent arrhythmias. *Diabetes Care*. 2014;37:516–520. doi: 10.2337/dc13-0600
22. Valensi PSG. Review: sulphonylureas and cardiovascular risk: facts and controversies. *Br J Diabetes Vasc*. 2006;6:159–165.
23. Xie F, Xu S, Lu Y, Wong KF, Sun L, Hasan KMM, Ma ACH, Tse G, Manno SHC, Tian L, et al. Metformin accelerates zebrafish heart regeneration by inducing autophagy. *NPJ Regen Med*. 2021;6:62. doi: 10.1038/s41536-021-00172-w
24. Xu S, Liu C, Xie F, Tian L, Manno SH, Manno FAM III, Fallah S, Pelster B, Tse G, Cheng SH. Excessive inflammation impairs heart regeneration in zebrafish breakdance mutant after cryoinjury. *Fish Shellfish Immunol*. 2019;89:117–126. doi: 10.1016/j.fsi.2019.03.058
25. Wang H, Wang C, Lu Y, Yan Y, Leng D, Tian S, Zheng D, Wang Z, Bai Y. Metformin shortens prolonged QT interval in diabetic mice by inhibiting L-type calcium current: a possible therapeutic approach. *Front Pharmacol*. 2020;11:614. doi: 10.3389/fphar.2020.00614
26. Nantsupawat T, Wongcharoen W, Chattipakorn SC, Chattipakorn N. Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. *Cardiovasc Diabetol*. 2020;19:198. doi: 10.1186/s12933-020-01176-4
27. Ostropelets A, Elias PA, Reyes MV, Wan EY, Pajvani UB, Hripcsak G, Morrow JP. Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. *Circ Arrhythm Electrophysiol*. 2021;14:e009115. doi: 10.1161/circep.120.009115
28. Eroglu TE, Jia L, Blom MT, Verkerk AO, Devalla HD, Boink GJJ, Souverein PC, de Boer A, Tan HL. Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: real-world data from a population-based study. *Br J Clin Pharmacol*. 2021;87:3588–3598. doi: 10.1111/bcp.14774
29. Magliano DJ, Islam RM, Barr ELM, Gregg EW, Pavkov ME, Harding JL, Tabesh M, Koye DN, Shaw JE. Trends in incidence of total or type 2 diabetes: systematic review. *BMJ*. 2019;366:15003. doi: 10.1136/bmj.15003
30. Adamczak DM, Oko-Sarnowska Z. Sudden cardiac death in hypertrophic cardiomyopathy. *Cardiol Rev*. 2018;26:145–151. doi: 10.1097/CRD.0000000000000184
31. Kadakia RS, Link MS, Dominic P, Morin DP. Sudden cardiac death in nonischemic cardiomyopathy. *Prog Cardiovasc Dis*. 2019;62:235–241. doi: 10.1016/j.pcad.2019.05.002
32. Feng XF, Hai JJ, Ma Y, Wang ZQ, Tse HF. Sudden cardiac death in mainland china: a systematic analysis. *Circ Arrhythm Electrophysiol*. 2018;11:e006684. doi: 10.1161/CIRCEP.118.006684
33. Martinez-Useros C, Tornos P, Montoyo J, Permanyer Miralda G, Alijarde M, Garcia del Castillo H, Moreno V, Soler-Soler J. Ventricular arrhythmias in aortic valve disease: a further marker of impaired left ventricular function. *Int J Cardiol*. 1992;34:49–56. doi: 10.1016/0167-5273(92)90081-d
34. Grigioni F, Enriquez-Sarano M, Ling LH, Bailey KR, Seward JB, Tajik AJ, Frye RL. Sudden death in mitral regurgitation due to flail leaflet. *J Am Coll Cardiol*. 1999;34:2078–2085. doi: 10.1016/s0735-1097(99)00474-x
35. Sriram CS, Syed FF, Ferguson ME, Johnson JN, Enriquez-Sarano M, Cetta F, Cannon BC, Asirvatham SJ, Ackerman MJ. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. *J Am Coll Cardiol*. 2013;62:222–230. doi: 10.1016/j.jacc.2013.02.060
36. Basso C, Iliceto S, Thiene G, Perazzolo MM. Mitral valve prolapse, ventricular arrhythmias, and sudden death. *Circulation*. 2019;140:952–964. doi: 10.1161/CIRCULATIONAHA.118.034075
37. Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, Moore LM, Rajpathak S. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. *Curr Med Res Opin*. 2016;32:1243–1252. doi: 10.1185/03007995.2016.1168291
38. Kuriachan VP, Sumner GL, Mitchell LB. Sudden cardiac death. *Curr Probl Cardiol*. 2015;40:133–200. doi: 10.1016/j.cpcardiol.2015.01.002
39. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93:137–188. doi: 10.1152/physrev.00045.2011
40. Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. *Diabetologia*. 2014;57:2465–2474. doi: 10.1007/s00125-014-3369-7
41. Ghuran AV, Camm AJ. Ischaemic heart disease presenting as arrhythmias. *Br Med Bull*. 2001;59:193–210. doi: 10.1093/bmb/59.1.193
42. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B, American Heart Association Clinical Pharmacology Committee of the Council on Clinical C, Council on C, Stroke N. Drug-induced arrhythmias: a scientific statement from the American Heart Association. *Circulation*. 2020;142:e214–e233. doi: 10.1161/CIR.0000000000000905
43. Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, et al. Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study. *Clin Ther*. 2017;39:759–770. doi: 10.1016/j.clinthera.2017.02.008
44. Wilkinson S, Douglas I, Stirnadel-Farrant H, Fogarty D, Pokrajac A, Smeeth L, Tomlinson L. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017. *BMJ Open*. 2018;8:e022768. doi: 10.1136/bmjopen-2018-022768
45. Mok KY, Chan PF, Lai LKP, Chow KL, Chao DVK. Prevalence of diabetic nephropathy among Chinese patients with type 2 diabetes mellitus and different categories of their estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in primary care in Hong Kong: a cross-sectional study. *J Diabetes Metab Disord*. 2019;18:281–288. doi: 10.1007/s40200-018-00382-y
46. Bramlage P, Lanzinger S, van Mark G, Hess E, Fahrner S, Heyer CHJ, Friebe M, Seufert J, Danne T, Holl RW. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. *Cardiovasc Diabetol*. 2019;18:33. doi: 10.1186/s12933-019-0837-x
47. Min T, Davies GI, Rice S, Chess J, Stephens JW. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: analysis of the SAIL patient linked dataset. *Diabetes Metab Syndr*. 2018;12:123–127. doi: 10.1016/j.dsx.2017.11.002
48. Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. *Ann Intern Med*. 2021;174:385–394. doi: 10.7326/M20-5938
49. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. *Pacing Clin Electrophysiol*. 2005;28:926–932. doi: 10.1111/j.1540-8159.2005.00195.x
50. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab*. 2018;20:1040–1043. doi: 10.1111/dom.13160
51. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. *Diabetes Ther*. 2013;4:175–194. doi: 10.1007/s13300-013-0034-y
52. Chao TF, Liu CJ, Tuan TC, Chen SJ, Chen TJ, Lip GYH, Chen SA. Risk and prediction of sudden cardiac death and ventricular arrhythmias for patients with atrial fibrillation—a nationwide cohort study. *Sci Rep*. 2017;7:46445. doi: 10.1038/srep46445

# SUPPLEMENTAL MATERIAL

**Table S1. International Classification of Diseases 9 (ICD-9) codes used for classifying outcomes and comorbidities.**

<b>Medical condition</b>	<b>ICD-9 codes</b>
<b>Outcome</b>	
VA/SCD	427.01,427.40-427.59
<b>Comorbidities</b>	
Peripheral vascular disease	250.7
Ischemic stroke	433.01,433.11,433.21,433.31, 433.81, 433.91, 434.01, 434.11, 435, 436
Atrial fibrillation	427.31, 429.4
Heart failure	428.00-428.99
Prior VA/SCD	427.01,427.40-427.59
Intracranial hemorrhage	430,431,432.0,432.1,432.9,852.0-852.1,852.2-852.3,852.4-852.5,853.0
Coronary heart disease	410.0-411.9,413.0-414.9
Hypertension	401.9
Chronic Obstructive Pulmonary Disease	491.00-492.99
Cardiomyopathy	425.0-425.9
Valvular disease	424.0-424.4

VA/SCD: Ventricular arrhythmia or sudden cardiac death

**Table S2. Baseline characteristics of metformin and sulfonylurea users with missing values for HbA1c.**

<b>Characteristics</b>	<b>Metformin (N=31984)</b>	<b>Sulfonylurea (N=22277)</b>
<b><i>Demographics</i></b>		
Male, N (%)	13533 (42.3%)	10628 (47.7%)
Baseline age, years	64.84±11.67	69.17±11.87
Follow up duration since type 2 diabetes diagnosis, years	4.77±2.55	4.83±2.56
<b><i>Comorbidities</i></b>		
Peripheral vascular disease, N (%)	6 (0.0%)	4 (0.0%)
Ischemic stroke, N (%)	611 (1.9%)	704 (3.2%)
Atrial fibrillation, N (%)	379 (1.2%)	573 (2.6%)
Heart failure, N (%)	462 (1.4%)	804 (3.6%)
Prior VA/SCD, N (%)	1 (0.0%)	6 (0.0%)
Intracranial hemorrhage, N (%)	273 (0.9%)	318 (1.4%)
Coronary heart disease, N (%)	1189 (3.7%)	1295 (5.8%)
Hypertension, N (%)	5190 (16.2%)	4703 (21.1%)
Chronic obstructive pulmonary disease, N (%)	68 (0.2%)	87 (0.4%)
<b><i>Medications</i></b>		
ACE inhibitors, N (%)	12114 (37.9%)	8060 (36.2%)
Beta blockers, N (%)	10609 (33.2%)	6913 (31.0%)
Calcium channel blockers, N (%)	13250 (41.4%)	9617 (43.2%)
Diuretics, N (%)	5473 (17.1%)	4185 (18.8%)
Insulin, N (%)	1547 (4.8%)	657 (2.9%)
Thiazolidinediones, N (%)	36 (0.1%)	29 (0.1%)
DPP4 inhibitors, N (%)	7 (0.0%)	4 (0.0%)
GLP-1 agonists, N (%)	0 (0.0%)	0 (0.0%)



**Table S3. Baseline characteristics of metformin and sulfonylurea users stratified by insulin versus insulin nonusers after 1:1 propensity score matching.**

Characteristics	Insulin users		Insulin nonusers	
	Metformin (N=2,429)	Sulfonylurea (N=2,501)	Metformin (N=14,167)	Sulfonylurea (N=14,095)
<b>Demographics</b>				
Male , N (%)	1303 (53.6%)	1359 (54.3%)	6608 (46.6%)	6913 (49.0%)
Baseline age, years	70.73±9.83	71.11±10.86	67.70±11.00	69.33±11.41
Follow up duration since type 2 diabetes diagnosis, years	4.95±2.49	4.93±2.56	4.92±2.55	4.93±2.55
<b>Comorbidities</b>				
Peripheral vascular disease, N (%)	29 (1.2%)	27 (1.1%)	0 (0.0%)	0 (0.0%)
Ischemic stroke, N (%)	156 (6.4%)	204 (8.2%)	703 (5.0%)	782 (5.5%)
Atrial fibrillation, N (%)	138 (5.7%)	194 (7.8%)	596 (4.2%)	772 (5.5%)
Heart failure, N (%)	238 (9.8%)	382 (15.3%)	557 (3.9%)	877 (6.2%)
Prior VA/SCD, N (%)	0 (0.0%)	3 (0.1%)	4 (0.0%)	4 (0.0%)
Intracranial hemorrhage, N (%)	47 (1.9%)	60 (2.4%)	259 (1.8%)	302 (2.1%)
Coronary heart disease, N (%)	441 (18.2%)	537 (21.5%)	1747 (12.3%)	1992 (14.1%)
Hypertension, N (%)	1149 (47.3%)	1359 (54.3%)	4755 (33.6%)	5178 (36.7%)
Chronic obstructive pulmonary disease, N (%)	11 (0.5%)	18 (0.7%)	47 (0.3%)	72 (0.5%)
<b>Medications</b>				
ACE inhibitors, N (%)	1827 (75.2%)	1518 (60.7%)	7021 (49.6%)	7507 (53.3%)
Beta blockers, N (%)	980 (40.3%)	1238 (49.5%)	5858 (41.3%)	5599 (39.7%)
Calcium channel blockers, N (%)	1335 (55.0%)	1450 (58.0%)	6194 (43.7%)	6360 (45.1%)
Diuretics, N (%)	928 (38.2%)	1188 (47.5%)	2833 (20.0%)	3104 (22.0%)
Thiazolidinediones, N (%)	95 (3.9%)	41 (1.6%)	74 (0.5%)	135 (1.0%)
DPP4 inhibitors, N (%)	6 (0.2%)	3 (0.1%)	6 (0.0%)	7 (0.0%)
GLP-1 agonists, N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Laboratory tests</b>				
HbA1c, %	7.44±1.42	7.44±1.45	7.45±1.44	7.45±1.45

Continuous variables were expressed as mean ± standard deviation. VA/SCD: Ventricular arrhythmia or sudden cardiac death; ACE: angiotensin-converting enzyme; DPP4: dipeptidyl-peptidase 4; GLP-1: glucagon-like peptide 1.

**Table S4. Baseline characteristics of metformin and sulfonylurea users stratified by history of coronary heart disease (CHD) after 1:1 propensity score matching.**

Characteristics	With CHD		Without CHD	
	Metformin (N=2,188)	Sulfonylurea (N=2,529)	Metformin (N=14,408)	Sulfonylurea (N=14,067)
<b>Demographics</b>				
Male, N (%)	1144 (52.3%)	1376 (54.4%)	6767 (47.0%)	6896 (49.0%)
Baseline age, years	71.03±9.72	72.46±9.87	67.70±10.99	69.08±11.52
Follow up duration since type 2 diabetes diagnosis, years	5.06±2.51	5.02±2.55	4.90±2.55	4.91±2.55
<b>Comorbidities</b>				
Peripheral vascular disease, N (%)	7 (0.3%)	10 (0.4%)	22 (0.2%)	17 (0.1%)
Ischemic stroke, N (%)	153 (7.0%)	167 (6.6%)	706 (4.9%)	819 (5.8%)
Atrial fibrillation, N (%)	202 (9.2%)	294 (11.6%)	532 (3.7%)	672 (4.8%)
Heart failure, N (%)	309 (14.1%)	583 (23.1%)	486 (3.4%)	676 (4.8%)
Prior VA/SCD, N (%)	4 (0.2%)	5 (0.2%)	0 (0.0%)	2 (0.0%)
Intracranial hemorrhage, N (%)	52 (2.4%)	63 (2.5%)	254 (1.8%)	299 (2.1%)
Hypertension, N (%)	1313 (60.0%)	1558 (61.6%)	4591 (31.9%)	4979 (35.4%)
Chronic obstructive pulmonary disease, N (%)	10 (0.5%)	27 (1.1%)	48 (0.3%)	63 (0.4%)
<b>Medications</b>				
ACE inhibitors, N (%)	1429 (65.3%)	1689 (66.8%)	7419 (51.5%)	7336 (52.2%)
Beta blockers, N (%)	1568 (71.7%)	1686 (66.7%)	5270 (36.6%)	5151 (36.6%)
Calcium channel blockers, N (%)	1071 (48.9%)	1334 (52.7%)	6458 (44.8%)	6476 (46.0%)
Diuretics, N (%)	632 (28.9%)	976 (38.6%)	3129 (21.7%)	3316 (23.6%)
Insulin, N (%)	441 (20.2%)	537 (21.2%)	1988 (13.8%)	1964 (14.0%)
Thiazolidinediones, N (%)	15 (0.7%)	17 (0.7%)	154 (1.1%)	159 (1.1%)
DPP4 inhibitors, N (%)	1 (0.0%)	3 (0.1%)	11 (0.0%)	7 (0.0%)
GLP-1 agonists, N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Laboratory tests</b>				
HbA1c, %	7.50±1.42	7.51±1.50	7.44±1.44	7.44±1.45

Continuous variables were expressed as mean ± standard deviation. VA/SCD: Ventricular arrhythmia or sudden cardiac death; ACE: angiotensin-converting enzyme; DPP4: dipeptidyl-peptidase 4; GLP-1: glucagon-like peptide 1.

**Table S5. Baseline characteristics of individual sulfonylurea users after 1:1 propensity score matching.**


<b>Characteristics</b>	<b>Glicazide (N=10116)</b>	<b>Glipizide (N=399)</b>	<b>Tolbutamide (N=302)</b>	<b>Glibenclamide (N=1216)</b>	<b>Glimepiride (N=180)</b>
<b><i>Demographics</i></b>					
Male, N (%)	4942 (48.9%)	200 (50.1%)	144 (47.7%)	633 (52.1%)	97 (53.9%)
Baseline age, years	70.05±11.40	72.66±11.77	73.34±11.29	67.36±10.30	69.42±11.05
Follow up duration since type 2 diabetes diagnosis, years	4.94±2.54	5.01±2.59	4.98±2.56	5.06±2.67	4.61±2.57
<b><i>Comorbidities</i></b>					
Peripheral vascular disease, N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Ischemic stroke, N (%)	648 (6.4%)	27 (6.8%)	20 (6.6%)	32 (2.6%)	9 (5.0%)
Atrial fibrillation, N (%)	622 (6.1%)	22 (5.5%)	32 (10.6%)	36 (3.0%)	3 (1.7%)
Heart failure, N (%)	729 (7.2%)	33 (8.3%)	34 (11.3%)	28 (2.3%)	10 (5.6%)
Prior VA/SCD, N (%)	4 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Intracranial hemorrhage, N (%)	244 (2.4%)	13 (3.3%)	6 (2.0%)	19 (1.6%)	4 (2.2%)
Coronary heart disease, N (%)	1492 (14.7%)	71 (17.8%)	60 (19.9%)	143 (11.8%)	21 (11.7%)
Hypertension, N (%)	3968 (39.2%)	170 (42.6%)	187 (61.9%)	355 (29.2%)	60 (33.3%)
Chronic obstructive pulmonary disease, N (%)	69 (0.7%)	0 (0.0%)	1 (0.3%)	1 (0.1%)	0 (0.0%)
<b><i>Medications</i></b>					
ACE inhibitors, N (%)	5457 (53.9%)	227 (56.9%)	167 (55.3%)	587 (48.3%)	116 (64.4%)
Beta blockers, N (%)	4025 (39.8%)	173 (43.4%)	163 (54.0%)	427 (35.1%)	91 (50.6%)
Calcium channel blockers, N (%)	4672 (46.2%)	203 (50.9%)	214 (70.9%)	494 (40.6%)	102 (56.7%)
Diuretics, N (%)	2362 (23.3%)	119 (29.8%)	126 (41.7%)	182 (15.0%)	64 (35.6%)
Insulin, N (%)	495 (4.9%)	37 (9.3%)	36 (11.9%)	31 (2.5%)	44 (24.4%)
Thiazolidinediones, N (%)	81 (0.8%)	8 (2.0%)	1 (0.3%)	7 (0.6%)	12 (6.7%)
DPP4 inhibitors, N (%)	3 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
GLP-1 agonists, N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

<i>Laboratory tests</i>					
HbA1c, %	7.45±1.46	7.54±1.56	7.62±1.52	7.40±1.44	7.53±1.47

VA/SCD: Ventricular arrhythmia or sudden cardiac death; ACE: angiotensin-converting enzyme; DPP4: dipeptidyl-peptidase 4; GLP-1: glucagon-like peptide



**Figure S1. Covariate balance before and after propensity score matching.**



VA/SCD: Ventricular arrhythmia or sudden cardiac death; ACE: angiotensin-converting enzyme; COPD: chronic obstructive pulmonary disease; DPP4: dipeptidyl-peptidase 4; GLP-1: glucagon-like peptide 1.